title: Deal watch: Bristol-Myers Squibb invests in cancer antibody that targets the innate immune system.
mesh_terms: D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic; D004345:Drug Industry / Q000191:economics / Q000639:trends*; D005805:Genes, MHC Class I; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects*; D007167:Immunotherapy; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C558235:IPH-2101